Form 8-K September 23, 2015	C.	
UNITED STATES		
SECURITIES AND EXCHA	NGE COMMISSION	
Washington, D.C. 20549		
FORM 8-K		
CURRENT REPORT		
Pursuant to Section 13 or 15((d) of the Securities Exchan	ge Act of 1934
Date of Report (Date of earlies	t event reported): September	17, 2015
CESCA THERAPEUTICS II	NC.	
(Exact name of registrant as sp	ecified in its charter)	
Delaware	333-82900	94-3018487
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
2711 Citrus Road		

Rancho Cordova, California 95742

(Address and telephone number of principal executive offices) (Zip Code)

1

<u>(916) 858</u> .	<u>-5100</u>
(Registran	nt's telephone number, including area code)
	appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of ant under any of the following provisions (see General Instruction A.2. below):
[] Pre-cor	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ng material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) nmencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) nmencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 9.01 Financial Statements and Exhibits.	
(d) Exhibits.	
79.1 Transcript dated September 17, 2015 for conference call titled, "Cesca Therapeutics Inc. Reports Fourth Quart and Full Fiscal Year 2015 Financial Results."	ter
	_

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cesca Therapeutics Inc. a Delaware Corporation

Dated: September 22, 2015 /s/ Michael Bruch Michael Bruch Interim Chief Financial Officer